Clinical trials: AMD
Intermediate AMD
MacuTherm Performance Study in Patients With iAMD
The goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors…
- Trial name
- NCT07607496
- Testing
- photothermal therapy
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 240 people
- Sponsor
- OD-OS MacuTherm GmbH
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
- Trial name
- SIENNA (NCT06541704)
- Testing
- Pozelimab, Cemdisiran
- Where
- 231 sites in United States, Australia and 9 more
- Volunteers
- 975 people
- Sponsor
- Regeneron Pharmaceuticals
AMD, Age-Related Macular Degeneration
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision…
- Trial name
- NCT04796545
- Testing
- SING IMT(TM) System, model NG SI IMT 3X
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- VisionCare, Inc.
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration (AMD)
Progression Suppression and Retinal Regression in VEGF-resistant AMD
The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.
- Trial name
- PRESERVE (NCT07005323)
- Testing
- Pars plana vitrectomy
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- PharmaBio Corporation
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD.
- Trial name
- NCT06659445
- Testing
- ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution
- Where
- 120 sites in United States, Austria and 10 more
- Volunteers
- 324 people
- Sponsor
- ONL Therapeutics
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Age-Related Macular Degeneration, Geographic Atrophy
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Trial name
- JOURNEY (NCT06087458)
- Testing
- VOY-101
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration.
- Trial name
- NCT07317934
- Testing
- LX102, Aflibercept
- Where
- 36 sites in China
- Volunteers
- 388 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Geographic Atrophy, Age - Related Macular Degeneration (AMD)
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2)…
- Trial name
- NCT07705568
- Testing
- PST-611
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Eyevensys
Dry Age-Related Macular Degeneration, AMD
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.
- Trial name
- NCT07700147
- Testing
- Transcutaneous Electrical Stimulation
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Nu Eyne Co., Ltd.
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- ARTEMIS (NCT06856577)
- Testing
- Ixo-vec, Aflibercept
- Where
- 75 sites in United States
- Volunteers
- 311 people
- Sponsor
- Adverum Biotechnologies, Inc.
Wet Age Related Macular Degeneration, Wet AMD
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
- Trial name
- NCT06704009
- Testing
- NT-101 Low Dose, NT-101 High Dose
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- NexThera Co., Ltd.
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT06817343
- Testing
- Aflibercept (2.0 mg)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
AMD
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.
- Trial name
- NCT07269769
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd